Leronlimab Talk - Dr. Nader Pourhassan CEO of CytoDyn

Find more lectures and answers to COVID-19 related questions on DrBeen.Com

DrBeen team and #koolbeens are super excited to have Dr. Pourhassan with us today. We will discuss Leronlimab with Dr. Pourhassan.

#koolbeens have asked a tons of questions to ask Dr. Pourhassan.

From CytoDyn’s site:
CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on developing Leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for a variety of indications. 

About CytoDyn
https://www.cytodyn.com/about-cytodyn

About Dr. Pourhassan
https://www.cytodyn.com/our-people/management-team

About Leronlimab
https://www.cytodyn.com/pipeline/covid-19

An excerpt from this page
The acute respiratory distress syndrome (ARDS) of COVID-19 results from the accumulation of neutrophils within the pulmonary circulation and alveolar spaces. Leronlimab (PRO 140) inhibits the migration of Tregs into areas of inflammation, which can inhibit the innate immune response against pathogens and, most importantly, the migration of macrophages and release of pro-inflammatory cytokines in lungs. Leronlimab can potentially mitigate the cytokine storm.